During the past decade, Hematology Oncology Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 100 clinical trials were completed, i.e. on average, 3333.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 22 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hematology Oncology Center" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 43 trials, followed by "National Cancer Institute (NCI)" with 39 trials sponsored, "SWOG Cancer Research Network" with 14 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 7 trials sponsored and "Eastern Cooperative Oncology Group" with 7 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hematology Oncology Center" #1 collaborator was "National Cancer Institute (NCI)" with 79 trials as a collaborator, "Cancer and Leukemia Group B" with 9 trials as a collaborator, "NCIC Clinical Trials Group" with 8 trials as a collaborator, "SWOG Cancer Research Network" with 8 trials as a collaborator and "NRG Oncology" with 5 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Hematology Oncology Center" are "Breast Cancer" (21 trials), "Unspecified Adult Solid Tumor, Protocol Specific" (10 trials), "Lung Cancer" (8 trials), "Lymphoma" (6 trials) and "Recurrent Breast Carcinoma" (6 trials). Many other conditions were trialed in "Hematology Oncology Center" in a lesser frequency.

Most popular intervention types in "Hematology Oncology Center" are "Drug" (101 trials), "Other" (60 trials), "Biological" (51 trials), "Radiation" (12 trials) and "Procedure" (11 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (29 trials), "placebo" (20 trials), "Bevacizumab" (14 trials), "Paclitaxel" (11 trials) and "bevacizumab" (11 trials). Other intervention names were less common.

The vast majority of trials in "Hematology Oncology Center" are 97 trials for "All" genders, 20 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Hematology Oncology Center". undefined are not yet recruiting, 1 are recruiting, 25 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 81 completed trials in Hematology Oncology Center, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Hematology Oncology Center, 4 "Phase 1" clinical trials were conducted, 50 "Phase 2" clinical trials and 58 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".